Charles Schwab
RCEL icon

Charles Schwab’s Avita Medical RCEL Stock Holding History

Charles Schwab’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.7K Sell
15,674
-30,632
-66% -$132K ﹤0.01% 3420
2026
Q1 		$171K Buy
46,306
+51
+0.1% +$214 ﹤0.01% 3320
2025
Q4 		$160K Buy
46,255
+621
+1% +$2.48K ﹤0.01% 3365
2025
Q3 		$233K Sell
45,634
-40,183
-47% -$210K ﹤0.01% 3334
2025
Q2 		$454K Buy
85,817
+21,602
+34% +$157K ﹤0.01% 3167
2025
Q1 		$523K Sell
64,215
-6,690
-9% -$62.5K ﹤0.01% 3071
2024
Q4 		$908K Hold
70,905
– – ﹤0.01% 2948
2024
Q3 		$760K Hold
70,905
– – ﹤0.01% 3006
2024
Q2 		$562K Buy
70,905
+3,605
+5% +$34.3K ﹤0.01% 3147
2024
Q1 		$1.08M Sell
67,300
-1,732
-3% -$28K ﹤0.01% 2773
2023
Q4 		$947K Hold
69,032
– – ﹤0.01% 2849
2023
Q3 		$1.01M Buy
69,032
+1,507
+2% +$25.5K ﹤0.01% 2796
2023
Q2 		$1.15M Buy
67,525
+57,471
+572% +$843K ﹤0.01% 2715
2023
Q1 		$140K Hold
10,054
– – ﹤0.01% 3208
2022
Q4 		$66.4K Hold
10,054
– – ﹤0.01% 3311
2022
Q3 		$53K Hold
10,054
– – ﹤0.01% 3321
2022
Q2 		$48K Sell
10,054
-53,225
-84% -$329K ﹤0.01% 3397
2022
Q1 		$537K Buy
63,279
+1,201
+2% +$11.1K ﹤0.01% 3079
2021
Q4 		$744K Sell
62,078
-164
-0.3% -$2.5K ﹤0.01% 3022
2021
Q3 		$1.1M Buy
62,242
+1,587
+3% +$29.9K ﹤0.01% 2838
2021
Q2 		$1.25M Buy
+60,655
New +$1.2M ﹤0.01% 2855

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab's RCEL Position: Q2 2026 in Review

Charles Schwab reduced its Avita Medical (RCEL) stake by 66% in Q2 2026, selling an estimated $132K and leaving 15,674 shares worth $64.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3420.

Charles Schwab first reported a position in RCEL in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.25M in Q2 2021. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • Charles Schwab held 15,674 shares of Avita Medical worth $64.7K as of Q2 2026.
  • Charles Schwab sold 30,632 Avita Medical shares in Q2 2026, an estimated $132K.
  • Avita Medical made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3420 holding.
  • Charles Schwab first reported a position in Avita Medical in Q2 2021 and has held it in 21 quarters since.
  • Charles Schwab's Avita Medical position peaked at $1.25M in Q2 2021.
  • 73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.